Data / Drug companies / Patheon Pharmaceuticals Inc.
Patheon Pharmaceuticals Inc.: 41 products in the FDA NDC directory, labeler code 67651
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Patheon Pharmaceuticals Inc. (labeler code 67651) lists 41 products in the FDA National Drug Code Directory. By type: 41 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on July 13, 2026.
The request: Watch Patheon Pharmaceuticals Inc. (FDA labeler code 67651): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 67651
- Products in commercial distribution
- 41
- Packages
- 46
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Controlled substance products
- Schedule II 4, Schedule IV 4
- Started marketing in the last 12 months
- 1
- Products with a marketing end date set
- 1
- Earliest marketing start
- August 21, 2009
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 41 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 41 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 17 | 41.5% |
| Capsule | 10 | 24.4% |
| Tablet | 5 | 12.2% |
| Tablet, film coated, extended release | 2 | 4.9% |
| Tablet, chewable | 2 | 4.9% |
| Tablet, delayed release | 2 | 4.9% |
| Granule, for suspension | 1 | 2.4% |
| Powder, for solution | 1 | 2.4% |
| Tablet, coated | 1 | 2.4% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Doravirine, islatravir | 67651-0416 | Tablet, film coated | Drugs for further processing | July 13, 2026 |
| Elexacaftor, tezacaftor, and ivacaftor | 67651-0405 | Tablet, film coated | Drugs for further processing | August 13, 2024 |
| Vanzacaftor, tezacaftor, and deutivacaftor | 67651-0396 | Tablet, film coated | Drugs for further processing | August 9, 2024 |
| Vanzacaftor, tezacaftor, and deutivacaftor | 67651-0397 | Tablet, film coated | Drugs for further processing | August 4, 2024 |
| Elexacaftor, tezacaftor, and ivacaftor | 67651-0404 | Tablet, film coated | Drugs for further processing | April 26, 2024 |
| Lisdexamfetamine dimesylate | 67651-0388 | Capsule | Drugs for further processing | February 19, 2024 |
| Lisdexamfetamine dimesylate | 67651-0387 | Capsule | Drugs for further processing | February 19, 2024 |
| Lisdexamfetamine dimesylate | 67651-0386 | Capsule | Drugs for further processing | February 19, 2024 |
| Suvorexant | 67651-0385 | Tablet, film coated | Drugs for further processing | January 20, 2024 |
| Suvorexant | 67651-0384 | Tablet, film coated | Drugs for further processing | January 20, 2024 |
| Suvorexant | 67651-0383 | Tablet, film coated | Drugs for further processing | January 20, 2024 |
| Suvorexant | 67651-0382 | Tablet, film coated | Drugs for further processing | January 20, 2024 |
| Tenapanor | 67651-0381 | Tablet, film coated | Drugs for further processing | October 17, 2023 |
| Tenapanor | 67651-0380 | Tablet, film coated | Drugs for further processing | October 17, 2023 |
| Tenapanor | 67651-0393 | Tablet, film coated | Drugs for further processing | September 25, 2023 |
| Pitolisant hydrochloride | 67651-0406 | Tablet, film coated | Drugs for further processing | August 27, 2023 |
| Omadacycline | 67651-0375 | Tablet, film coated | Drugs for further processing | September 27, 2022 |
| Molnupiravir | 67651-0365 | Capsule | Drugs for further processing | December 23, 2021 |
| Avacopan | 67651-0364 | Capsule | Drugs for further processing | October 18, 2021 |
| Avacopan | 67651-0363 | Capsule | Drugs for further processing | October 18, 2021 |
| Selumetinib | 67651-0344 | Capsule | Drugs for further processing | April 16, 2020 |
| Selumetinib | 67651-0343 | Capsule | Drugs for further processing | April 16, 2020 |
| Tenapanor hydrochloride | 67651-0335 | Tablet | Drugs for further processing | September 12, 2019 |
| Amifampridine phosphate | 67651-0328 | Tablet | Drugs for further processing | January 7, 2019 |
| Prucalopride succinate | 67651-0331 | Tablet, film coated | Drugs for further processing | December 14, 2018 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.